Vimarsana
Biggest News Aggregation in the World

Page 18 - Presentation Details News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Presentation Details. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Presentation Details Today - Breaking & Trending Today

Immune-Onc Therapeutics to Showcase Leadership in Myeloid Biology and Drug Development at Upcoming S - Vimarsana News

Immune-Onc Therapeutics to Showcase Leadership in Myeloid Biology and Drug Development at Upcoming S

PALO ALTO, Calif.--(BUSINESS WIRE)--#AML--Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, announced today its plans to present on the company’s myeloid biology research and clinical stage programs at...

BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the - Vimarsana News

BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that two abstracts...

BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting - Vimarsana News

BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting

BELLUS Health Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other cough hypersensitivity indications, today... | February 8, 2023

Exscientia plc: Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress - Vimarsana News

Exscientia plc: Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress

Uses multi-omics to identify a biomarker which could be predictive of '546 response in the clinic Differentiated '546 development and patient enrichment strategy driven by Exscientia's precision

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH - Vimarsana News

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH